Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Dr. Seely has served as President and CEO of Lyell Immunopharma since December 2022. She was previously President, CEO and board member of Myovant Sciences, where she oversaw the launch of ORGOVYX and MYFEMBREE. Prior to Myovant, she served as Chief Medical Officer of Medivation, overseeing the development and approval of XTANDI for prostate cancer.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Lyell Immunopharma, Inc.

2021-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Lyell Immunopharma, Inc.

Open Lyell Immunopharma, Inc. profile →

Director at Lyell Immunopharma, Inc.

2021-01-01 → End not stated

current · source reported

Observed: 2026-09-25

Lyell Immunopharma…Lyell Immunopharma, Inc.Lynn Seely, M.D.

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingLYEL DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:lynn-seely-m-d
Record version
public-0

Published evidence records

5 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. LYEL DEF 14A director slate

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 1, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 1, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 1, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Lyell Immunopharma, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 1, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. LYEL DEF 14A executive officers

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Lyell Immunopharma, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: President, Chief Executive Officer and Director · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. Lyell Immunopharma, Inc. director board source

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 3, 2026

    Supports 2 claims
    • Board independence: Not independent (executive director) · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Lyell Immunopharma, Inc. · Claim reviewed: May 3, 2026

  4. Open source

    sec proxy · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Lyell Immunopharma, Inc. · Claim reviewed: May 16, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Lyell Immunopharma, Inc. · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board independence · Source reportedNot independent (executive director)1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Lyell Immunopharma, Inc.Supported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 1, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 1, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at Lyell Immunopharma, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: President and Chief Executive Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 1, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

Executive title · Source reportedExecutive title: President, Chief Executive Officer and Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources5 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Director since · Board independence

  4. https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Lyell Immunopharma, Inc. (NASDAQ: LYEL)

  5. https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership